Zealand Pharma CEO: Zegalogue launch continues as planned

The seminal launch of hypoglycemia medication Zegalogue has thus far gone according to plan, informs biotech group Zealand Pharma CEO Emmanuel Dulac, who declines to disclose figures for the development thus far, however.
Photo: Stine Bidstrup/ERH
Photo: Stine Bidstrup/ERH
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL FRANK CHRISTENSEN

It's nearly two months back since last June when Zealand Pharma launched its hypoglycemia medication, Zegalogue, on the US market. According to the Danish biotechnology group's chief executive, Emmanuel Dulac, everything is going completely according to plan.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading